An Exploratory Phase 2/3, Randomized, Double-blind, Placebo Controlled, Parallel Design Study to Evaluate the Efficacy, Safety and Pharmacodynamics of Dapagliflozin and Dapagliflozin in Combination With Saxagliptin in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria Treated With ACEi or ARB
Latest Information Update: 07 Dec 2021
At a glance
- Drugs Dapagliflozin (Primary) ; Saxagliptin (Primary)
- Indications Proteinuria; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms DELIGHT
- Sponsors AstraZeneca
- 01 Aug 2021 Results of post-hoc exploratory analysis of three randomized studies (DELIGHT (NCT02547935), IMPROVE (Netherlands Trial Register NTR4439) and DIAMOND (NCT03190694)) published in the Diabetes, Obesity and Metabolism.
- 19 Apr 2018 Status changed from active, no longer recruiting to completed.
- 21 Dec 2017 Planned End Date changed from 28 Mar 2018 to 3 Apr 2018.